Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

Namrata Gautam on LinkedIn: T-cell Transfer Therapy - Immunotherapy

Treatment National Cancer Institute

Treatment National Cancer Institute

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant

PDF) Emerging and Future Targeted Therapies for Pediatric Acute

National Cancer Institute (NCI) on LinkedIn: Cancer Grand

Treatment National Cancer Institute

Clinical Trial Results - Cancer Currents Blog - NCI

Cancer Currents: An NCI Cancer Research Blog - NCI

Al Giovanniello on LinkedIn: Revumenib Shows Promise for Advanced

Clinical Trial Results National Cancer Institute

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant

Cancer Currents: An NCI Cancer Research Blog - NCI

Summary of in vitro and in vivo data of given compounds and

Primary Endpoint Met for Revumenib in Patients with AML and ALL